Latest Share Placement News

First Graphene Limited has raised A$3.5 million through a share placement to accelerate the commercial adoption of its PureGRAPH graphene products and support ongoing operations.

Critical Minerals Group has raised $2 million through a placement to accelerate key development milestones for its Lindfield Vanadium Project and vanadium flow battery supply chain.

Stellar Resources has raised $9 million through a share placement to advance development at its high-grade Heemskirk Tin Project in Tasmania, bolstered by strong investor demand amid rising tin prices.

Terrain Minerals has successfully raised $1.32 million through a share placement to fund exploration at its Smokebush Project, targeting high-grade gold and silver deposits.

Greenvale Energy has raised approximately $1.05 million through a share placement to fund ongoing uranium exploration at its Oasis project, with a Security Purchase Plan also offered to shareholders.

Sarytogan Graphite Limited has secured a $1.4 million top-up placement from the European Bank for Reconstruction and Development, reinforcing confidence in its graphite project and supporting its feasibility study timeline.

Encounter Resources has completed the first tranche of its $25 million share placement, raising approximately $24.5 million to advance its mineral exploration projects. The second tranche, involving shares to a company director, awaits shareholder approval.

Mount Hope Mining has issued over six million shares via placement and is set to offer additional shares through a share purchase plan, signaling a strategic capital raise.

Middle Island Resources has completed its acquisition of Konstantin Resources, issuing over 750 million new securities following shareholder approval. This marks a significant expansion in Middle Island's portfolio and capital structure.

ARC Funds Limited has strategically acquired $2.15 million face value of convertible notes in ausbiz TV at just 20% of their value, issuing 4.47 million new shares as consideration. This move aligns with ARC’s growth strategy to diversify income streams and deepen its investment platform.

Tryptamine Therapeutics has raised $6.1 million to fast-track clinical development of its IV-infused psilocin drug TRP-8803, targeting binge eating disorder and other neuropsychiatric conditions.

Austral Resources Australia Ltd is poised to resume trading on the ASX following a successful $40 million placement, marking a significant step in its recovery and future growth plans.